$SION

Sionna Therapeutics (Nasdaq: SION) will present data at the 2026 North American Cystic Fibrosis Conference. The company reported post hoc analyses of the PreciSION CF trial, showing an 8.6 mmol/L sweat chloride reduction with SION-719. Sionna plans to advance SION-451 + SION-2222 into a Phase 2a trial in early 2027. Preclinical data suggests potential benefits for a broad CF population.

RA CAPITAL MANAGEMENT, L.P. sold 3,448,811 indirectly-held shares of Sionna Therapeutics, Inc. (SION) at an average of $6.33 ($6.32–$7.46, $21.84M total) across 2 trades on 2026-09-17. Filed jointly with RA Capital Healthcare Fund LP (Director), RA Capital Nexus Fund, L.P. (Director), RA Capital Nexus Fund III, L.P. (Director), Kolchinsky Peter (Director) and Shah Rajeev M. (Director).

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo

Sionna Therapeutics (SION) announced a 46% workforce reduction to extend its cash runway to mid-2029. The company will focus on SION-451 and SION-2222 for cystic fibrosis, with a Phase 2a trial planned for Q1 2027. The restructuring aims to save $6.4M but carries risks related to trial outcomes and execution.

Sionna Therapeutics' stock fell 3% after-hours following a strategic reset, including a 46% workforce reduction and a shift in clinical trial focus. The company also confirmed it will not pursue SION-719. Raymond James downgraded the stock to Market Perform. The broader market showed minimal gains, with the S&P 500, Dow Jones, and Nasdaq each rising 0.1% or 0.2%.

Sionna Therapeutics (NASDAQ:SION) shares fell 3% after announcing a 46% workforce reduction and a pivot to a new cystic fibrosis drug combination, SION-451 + SION-2222, for a Phase 2a trial starting in Q1 2027. The company cited data from its PreciSION CF trial and expects $6.4M in restructuring charges, with cash runway extending into 2H 2029.

Sionna Therapeutics, Inc. (SION) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NB

Vertex Pharmaceuticals (VRTX) maintains dominance in the cystic fibrosis (CF) drug market. Sionna Therapeutics (SION) reported a phase 2 trial failure for its CF drug candidate, SION-719, causing its stock to drop 90%. Vertex's CF drugs, including Trikafta and Alyftrek, now target 95% of CF patients. Vertex is also expanding into other therapeutic areas, such as gene-editing therapy Casgevy for sickle cell disease and beta-thalassemia, developed with CRISPR Therapeutics (CRSP).

Sionna Therapeutics (SION) shares fell about 92% after it said its Phase 2a trial of SION-719 in 15 cystic fibrosis adults failed to meet its main goal. The add-on drug did not significantly improve sweat chloride versus placebo, so Sionna will not advance it. SION had $268M cash. Analysts cited reduced overhang for Vertex (VRTX).

Sionna Therapeutics (NASDAQ:SION) shares fell over 90% after its Phase 2a PreciSION CF trial of SION-719 as an add-on to Vertex’s Trikafta failed its main activity endpoint, so Sionna said it will not proceed SION-719. Vertex (NASDAQ:VRTX) rose to new highs as the CF competitive overhang eased. Sionna will prioritize SION-451; Vertex cited prior strength and guidance.